의료용 IoT 시장 예측(2026-2032년)

The Internet of Medical Things Market is projected to grow by USD 7.95 billion at a CAGR of 28.76% by 2032.

Internet of Medical Things Executive Summary

The Internet of Medical Things (IoMT) is reshaping healthcare delivery by connecting medical devices, wearable sensors, remote patient monitoring platforms, clinical systems, and analytics environments across secure digital networks. As healthcare systems respond to aging populations, rising chronic disease prevalence, clinician shortages, and demand for care outside hospital walls, IoMT has become a practical foundation for continuous monitoring, virtual care, medication adherence, connected diagnostics, and data-driven clinical workflows. Verified public health and regulatory signals support this transition: the World Health Organization identifies noncommunicable diseases as responsible for the majority of global deaths, while national health authorities continue to expand digital health, telehealth, cybersecurity, and interoperability guidance. Within this environment, IoMT is moving from isolated connected devices toward integrated care ecosystems that support earlier intervention, improved operational visibility, and patient-centered care models.

Transformative Shifts in the Internet of Medical Things Landscape

The IoMT landscape is undergoing transformative shifts driven by hospital-at-home models, remote patient monitoring, connected wearables, smart implants, software-enabled medical devices, and cloud-based care coordination. Health systems are increasingly prioritizing interoperability with electronic health records, standards-based data exchange, device identity management, and secure integration across clinical and home-care settings. Regulatory frameworks are also becoming more defined, with authorities emphasizing medical device cybersecurity, software lifecycle management, data privacy, and post-market surveillance. At the same time, consumer adoption of wearables and connected health tools is increasing patient familiarity with continuous health tracking. The most important shift is the movement from episodic care to longitudinal care, where connected medical devices help clinicians monitor deterioration risks, therapy response, rehabilitation progress, and chronic conditions between formal encounters.

Cumulative Impact of Artificial Intelligence on IoMT

Artificial intelligence is amplifying IoMT value by converting continuous device-generated data into clinically relevant insights. AI-enabled algorithms support anomaly detection, risk stratification, workflow prioritization, image interpretation, predictive maintenance of connected equipment, and personalized alerts for remote monitoring teams. The cumulative impact is especially significant in chronic disease management, cardiology monitoring, sleep care, diabetes management, respiratory monitoring, elder care, and intensive care environments where high-frequency data can overwhelm clinicians without intelligent filtering. However, the integration of AI into IoMT also increases the need for transparent model governance, validated clinical performance, bias monitoring, cybersecurity safeguards, and explainability. Regulators and health technology assessment bodies are placing greater emphasis on evidence generation, real-world performance monitoring, and responsible AI deployment, making trust, safety, and clinical validation essential for sustainable adoption.

Key Regional Insights for Internet of Medical Things

Asia-Pacific is advancing rapidly in IoMT adoption as large populations, expanding digital health infrastructure, high mobile connectivity, and government-led connected care initiatives accelerate remote monitoring and mobile health use. Countries across the region are using IoMT to address uneven access to specialists, chronic disease growth, aging demographics, and demand for scalable care delivery. North America remains a highly active IoMT environment due to mature digital health infrastructure, strong telehealth utilization, connected hospital investment, electronic health record penetration, and regulatory attention to medical device cybersecurity and interoperability. Latin America is seeing IoMT momentum through public and private telemedicine programs, mobile connectivity, and rising interest in remote care for diabetes, cardiovascular disease, and underserved communities, although infrastructure variation and reimbursement complexity remain important considerations. Europe is shaped by strong data protection requirements, digital health reimbursement pathways, cross-border health data initiatives, and emphasis on secure, interoperable medical devices under evolving medical device and data governance rules. The Middle East is investing in smart hospitals, national digital health platforms, and connected care as part of broader healthcare modernization programs, particularly in urban centers with advanced digital infrastructure. Africa's IoMT development is closely tied to mobile health, remote diagnostics, maternal health, infectious disease monitoring, and efforts to extend care access, with connectivity, affordability, local maintenance capacity, and device resilience representing key implementation factors.

Key Group Insights for Internet of Medical Things

ASEAN economies are using IoMT to support mobile-first healthcare access, connected diagnostics, and chronic disease monitoring across diverse urban and rural settings, with digital health strategies increasingly linked to universal health coverage goals and primary care strengthening. The GCC is prioritizing IoMT within smart hospital programs, national health transformation agendas, and advanced digital infrastructure investments, making remote monitoring, virtual care, and connected medical devices important components of preventive and personalized healthcare. The European Union is distinguished by coordinated digital health policy, strong privacy regulation, medical device regulation, cybersecurity guidance, and growing work around shared health data spaces, all of which influence IoMT design, compliance, and deployment. BRICS countries demonstrate varied but significant IoMT potential, supported by large patient populations, public health modernization, domestic technology capacity, and growing use of telehealth and connected devices to improve access in both urban and underserved settings. G7 countries generally lead in regulatory maturity, reimbursement experimentation, clinical evidence standards, privacy safeguards, and cybersecurity requirements for connected medical technologies. NATO member states are also relevant to IoMT through their focus on resilient health infrastructure, cyber defense, secure communications, emergency preparedness, and continuity of care where connected medical devices are part of critical health environments.

Key Country Insights for Internet of Medical Things

The United States is a leading IoMT adopter due to extensive use of remote patient monitoring, telehealth-enabled care models, electronic health record integration, hospital-at-home programs, and active regulatory guidance on connected medical device cybersecurity. Canada is emphasizing virtual care, remote monitoring for dispersed populations, and secure digital health systems across provincial healthcare structures. Mexico is expanding digital health capabilities as connected care becomes relevant for chronic disease management, access improvement, and mobile-enabled services. Brazil has growing IoMT relevance through telehealth expansion, mobile health adoption, and connected care needs across a large and geographically diverse population. The United Kingdom is advancing digital health through national health service modernization, virtual wards, remote monitoring pathways, and evidence-based technology assessment. Germany's IoMT environment is influenced by digital health reimbursement mechanisms, medical device regulation, hospital digitization, and strong privacy requirements. France is building momentum through digital health policy, reimbursement pathways, electronic health record initiatives, and connected care programs. Russia's IoMT activity is shaped by telemedicine, hospital digitization, and domestic technology development, though regulatory and infrastructure conditions vary. Italy and Spain are expanding remote monitoring and connected care to support aging populations, chronic disease management, and regional healthcare modernization. China is accelerating IoMT through large-scale digital health adoption, hospital connectivity, AI-enabled diagnostics, and strong demand for remote management of chronic conditions. India is using IoMT to expand access through mobile health, telemedicine, connected diagnostics, and public digital health infrastructure. Japan is highly relevant due to aging demographics, robotics-enabled care, connected monitoring, and advanced medical technology adoption. Australia is deploying IoMT to support remote care across geographically dispersed communities, chronic disease programs, and digitally enabled hospitals. South Korea is advancing connected healthcare through high broadband penetration, smart hospital initiatives, wearable technology adoption, and digitally mature health infrastructure.

Actionable Recommendations for IoMT Industry Leaders

Industry leaders should prioritize secure-by-design IoMT architecture, including device authentication, encryption, software bill of materials practices, vulnerability management, patch planning, and continuous monitoring across connected medical device ecosystems. Interoperability should be treated as a strategic requirement, with investment in standards-based data exchange, integration with clinical workflows, and compatibility across hospital, ambulatory, and home-care environments. Organizations should generate clinical evidence that demonstrates safety, usability, workflow impact, and patient outcomes rather than relying on connectivity alone as a value proposition. Partnerships with healthcare providers, payers, regulators, cybersecurity specialists, standards bodies, and patient advocacy groups can improve adoption readiness and trust. Leaders should also focus on human-centered design, multilingual patient engagement, accessibility, battery reliability, data minimization, alert fatigue reduction, and equitable access for digitally underserved populations. For AI-enabled IoMT, governance should include model validation, auditability, post-deployment monitoring, bias assessment, and clear escalation protocols for clinical users.

Research Methodology for Internet of Medical Things Analysis

This executive summary is developed using a structured secondary research methodology focused on verified, publicly available, and policy-relevant sources. Inputs include healthcare authority publications, medical device regulatory guidance, cybersecurity advisories, digital health policy documents, clinical practice trends, peer-reviewed literature, interoperability standards discussions, and publicly documented telehealth and remote monitoring initiatives. The research approach emphasizes triangulation across multiple credible sources to identify consistent patterns in IoMT adoption, technology integration, regulatory direction, and regional healthcare priorities. The analysis excludes market sizing, market share, and forecasting, and instead focuses on qualitative evidence, implementation drivers, policy context, technology trends, and operational implications for stakeholders across the Internet of Medical Things ecosystem.

Conclusion: The Future of Connected Healthcare Through IoMT

The Internet of Medical Things is becoming a core enabler of connected, preventive, and patient-centered healthcare. Its progress is supported by remote patient monitoring demand, smart medical devices, virtual care models, interoperability initiatives, cybersecurity modernization, and AI-enabled analytics, while its risks center on privacy, validation, equity, device lifecycle management, and clinical workflow integration. Regions and countries are advancing at different speeds, but the global direction is clear: healthcare delivery is moving toward continuous, data-informed engagement across hospitals, homes, and community settings. Organizations that combine regulatory discipline, cybersecurity resilience, clinical evidence, interoperability, and patient usability will be best positioned to create sustainable value in the evolving IoMT ecosystem.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. New Revenue Opportunities
• 3.5. Next-Generation Business Models
• 3.6. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Internet of Medical Things Market, by Device Type

• 7.1. Introduction
• 7.2. Medical Devices
  • 7.2.1. Implantable Devices
  • 7.2.2. Stationary Devices
  • 7.2.3. Wearable Devices
• 7.3. Services
  • 7.3.1. Professional Services
  • 7.3.2. Managed Services
• 7.4. Platform & Software
  • 7.4.1. Device Management Platforms
  • 7.4.2. Data Analytics Platforms
  • 7.4.3. Remote Patient Monitoring Software
  • 7.4.4. Security & Compliance Software

8. Internet of Medical Things Market, by Component

• 8.1. Introduction
• 8.2. Connectivity Modules
• 8.3. Sensors
• 8.4. Services
• 8.5. Software

9. Internet of Medical Things Market, by Connectivity Technology

• 9.1. Introduction
• 9.2. Bluetooth Low Energy
• 9.3. Cellular IoT
• 9.4. LPWAN
• 9.5. Wi-Fi
• 9.6. Zigbee

10. Internet of Medical Things Market, by Data Type

• 10.1. Introduction
• 10.2. Biometric
• 10.3. Motion & Location Data
• 10.4. Device Operational Data
• 10.5. Environmental Data

11. Internet of Medical Things Market, by Application

• 11.1. Introduction
• 11.2. Asset Tracking
• 11.3. Chronic Disease Management
• 11.4. Drug Delivery
• 11.5. Remote Patient Monitoring
• 11.6. Surgical Telemetry

12. Internet of Medical Things Market, by End Use

• 12.1. Introduction
• 12.2. Clinics
• 12.3. Diagnostics Centers
• 12.4. Home Healthcare
• 12.5. Hospitals

13. Internet of Medical Things Market, by Region

• 13.1. Asia-Pacific
• 13.2. North America
• 13.3. Latin America
• 13.4. Europe
• 13.5. Middle East
• 13.6. Africa

14. Internet of Medical Things Market, by Group

• 14.1. ASEAN
• 14.2. GCC
• 14.3. European Union
• 14.4. BRICS
• 14.5. G7
• 14.6. NATO

15. Internet of Medical Things Market, by Country

• 15.1. United States
• 15.2. Canada
• 15.3. Mexico
• 15.4. Brazil
• 15.5. United Kingdom
• 15.6. Germany
• 15.7. France
• 15.8. Russia
• 15.9. Italy
• 15.10. Spain
• 15.11. China
• 15.12. India
• 15.13. Japan
• 15.14. Australia
• 15.15. South Korea

16. Competitive Landscape

• 16.1. Market Share Analysis, 2025
• 16.2. FPNV Positioning Matrix, 2025
• 16.3. Market Concentration Analysis, 2025
  • 16.3.1. Concentration Ratio (CR)
  • 16.3.2. Herfindahl Hirschman Index (HHI)
• 16.4. Recent Developments & Impact Analysis, 2025
• 16.5. Product Portfolio Analysis, 2025
• 16.6. Benchmarking Analysis, 2025

17. Company Profiles

• 17.1. Abbott Laboratories
• 17.2. AliveCor, Inc.
• 17.3. Baxter International Inc.
• 17.4. Becton, Dickinson and Company
• 17.5. Biotronik SE & Co. KG
• 17.6. Boston Scientific Corporation
• 17.7. Cisco Systems, Inc.
• 17.8. DexCom Inc.
• 17.9. Edwards Lifesciences Corporation
• 17.10. F. Hoffmann-La Roche Ltd.
• 17.11. GE HealthCare Technologies Inc.
• 17.12. Honeywell International Inc.
• 17.13. IBM Corporation
• 17.14. Intel Corporation
• 17.15. Intuitive Surgical, Inc.
• 17.16. iRhythm Technologies, Inc.
• 17.17. Johnson & Johnson
• 17.18. Koninklijke Philips N.V.
• 17.19. Masimo Corporation
• 17.20. Medtronic plc
• 17.21. Microsoft Corporation
• 17.22. Omron Healthcare, Inc.
• 17.23. Oracle Corporation
• 17.24. Qualcomm Life, Inc.
• 17.25. ResMed Inc.
• 17.26. Siemens Healthineers AG
• 17.27. Smith & Nephew plc
• 17.28. Stryker Corporation
• 17.29. Terumo Corporation
• 17.30. Zimmer Biomet Holdings, Inc.